Open AccessBone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Author(s) -
Angel Qin,
Songzhu Zhao,
Abdul Miah,
Lai Wei,
Sandipkumar Patel,
Andrew Johns,
Madison Grogan,
Erin M. Bertino,
Kaitlyn He,
Peter G. Shields,
Gregory P. Kalemkerian,
Shirish M. Gadgeel,
Nithya Ramnath,
Bryan J. Schneider,
Khaled A. Hassan,
Nicholas Szerlip,
Zoey Chopra,
Sara N. Journey,
Jessica Waninger,
Daniel Spakowicz,
David P. Carbone,
Carolyn J. Presley,
Gregory A. Otterson,
Michael D. Green,
Dwight H. Owen
Publication year - 2021
Publication title -
journal of the national comprehensive cancer network
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.707
H-Index - 109
eISSN - 1540-1413
pISSN - 1540-1405
DOI - 10.6004/jnccn.2020.7668
Subject(s) - medicine , oncology , hazard ratio , proportional hazards model , retrospective cohort study , cohort , lung cancer , nivolumab , cancer , surgery , confidence interval , immunotherapy
Bone metastases and skeletal-related events (SREs) are a frequent cause of morbidity in patients with metastatic non-small cell lung cancer (mNSCLC). Data are limited on bone metastases and SREs in patients with mNSCLC treated using immune checkpoint inhibitors (ICIs), and on the efficacy of bone-modifying agents (BMAs) in this setting. Here we report the incidence, impact on survival, risk factors for bone metastases and SREs, and impact of BMAs in patients with mNSCLC treated with ICIs in a multi-institutional cohort.